STAAR Surgical (STAA) Posted A Standout Quarter, Is The Stock Cheap Enough?
STAAR Surgical (STAA) just posted what management described as its strongest quarter in its peer group, with revenue of $93.54 million, up 111% year on year and 3.3% above analyst expectations.
STAAR Surgical’s latest report dropped into a share price that has been under pressure, with the stock down 19.4% on a 90-day share price return and the 1-year total shareholder return declining 14.5%, despite the strong quarter and a new leadership hire in business development.
Capitalize on the gap between STAAR Surgical’s strong quarter and weak share price by scanning a handpicked 20 high quality undiscovered gems that show solid fundamentals but muted sentiment.STAAR Surgical just paired a very strong quarter with a share price that has fallen hard. Does it make more sense to lean into that disconnect now, or wait for an even cheaper entry before the valuation work checks out?
Most Popular Narrative: 20% Undervalued
On the most followed view, STAAR Surgical’s fair value of $28 sits well above the last close at $22.38. This puts the current share price at a clear discount while still assuming a relatively demanding outlook.
The Nidau, Switzerland facility is planned to supply all EVO and EVO+ lenses shipped to China by the end of 2026, which would remove China tariffs on those products and has the potential to lift gross margin and net income once higher cost inventory is worked through.
See why 8 investors see STAAR Surgical as 20% undervalued.
Result: Fair Value of $28 (UNDERVALUED)
Still, if a shift in China mix stalls or margins remain pressured by tariffs and higher cost inventory for longer than expected, the STAAR Surgical rerating case weakens.
Find out about the key risks to this STAAR Surgical narrative.
Another View: STAAR Surgical Through The Sales Multiple Lens
There is a catch. On a simple P/S check, STAAR Surgical trades at 3.3x sales. This sits above the US Medical Equipment industry on 2.6x and peers on 3.1x, and above a fair ratio of 2.9x that the market could move toward as expectations reset.
If the share price drifts closer to that 2.9x fair ratio, investors are effectively paying less for each dollar of revenue. If it stays at a premium instead, that richer tag raises the bar for future execution.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Mixed signals on STAAR Surgical so far. If you want to move before sentiment flips either way, consider both the potential upside and the concerns, and pressure test each using 3 key rewards and 1 important warning sign.
Looking for more STAAR Surgical investment ideas?
If you want more angles beyond STAAR Surgical, move quickly and use the Simply Wall St Screener to surface focused shortlists that match your investing style.
- Target high quality at a discount and line up potential candidates using the 27 high quality undervalued stocks that filters for strength and mispriced opportunity.
- Prioritise resilience by running through the 31 resilient stocks with low risk scores that highlights businesses with sturdier financial profiles and lower overall risk scores.
- Hunt for financially sound outliers that the market has not fully appreciated yet through the curated 20 high quality undiscovered gems list.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com